{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:38:33Z","timestamp":1781739513979,"version":"3.54.5"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11060-025-05362-w","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:40:30Z","timestamp":1764938430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhancing radiation sensitivity in malignant brain tumors with chloroquine: a systematic review"],"prefix":"10.1007","volume":"176","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4683-2115","authenticated-orcid":false,"given":"Paul M.","family":"Harary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9921-6810","authenticated-orcid":false,"given":"Yusuke S.","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas","family":"Annagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7345-0158","authenticated-orcid":false,"given":"Yuki","family":"Tatekoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Hosoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukika","family":"Saga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-2592","authenticated-orcid":false,"given":"David J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6873-1297","authenticated-orcid":false,"given":"Atsushi","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4315-681X","authenticated-orcid":false,"given":"Steven D.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"5362_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","volume":"10","author":"M Weller","year":"2024","unstructured":"Weller M, Wen PY, Chang SM et al (2024) Glioma. Nat Reviews Disease Primers 10:33","journal-title":"Nat Reviews Disease Primers"},{"key":"5362_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canlet.2012.12.024","volume":"331","author":"Y Wang","year":"2013","unstructured":"Wang Y, Jiang T (2013) Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett 331:139\u2013146","journal-title":"Cancer Lett"},{"key":"5362_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrclinonc.2012.87","volume":"9","author":"C Jones","year":"2012","unstructured":"Jones C, Perryman L, Hargrave D (2012) Paediatric and adult malignant glioma: close relatives or distant cousins? Nat Reviews Clin Oncol 9:400\u2013413","journal-title":"Nat Reviews Clin Oncol"},{"key":"5362_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41568-019-0220-y","volume":"20","author":"A Boire","year":"2020","unstructured":"Boire A, Brastianos PK, Garzia L, Valiente M (2020) Brain metastasis. Nat Rev Cancer 20:4\u201311","journal-title":"Nat Rev Cancer"},{"key":"5362_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/OP.22.00476","volume":"19","author":"R Kotecha","year":"2023","unstructured":"Kotecha R, Odia Y, Khosla AA, Ahluwalia MS (2023) Key clinical principles in the management of glioblastoma. JCO Oncol Pract 19:180\u2013189","journal-title":"JCO Oncol Pract"},{"key":"5362_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan AC, Ashley DM, L\u00f3pez GY et al (2020) Management of glioblastoma: state of the art and future directions. Cancer J Clin 70:299\u2013312","journal-title":"Cancer J Clin"},{"key":"5362_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","volume":"17","author":"JH Suh","year":"2020","unstructured":"Suh JH, Kotecha R, Chao ST et al (2020) Current approaches to the management of brain metastases. Nat Reviews Clin Oncol 17:279\u2013299","journal-title":"Nat Reviews Clin Oncol"},{"key":"5362_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1748-717X-7-77","volume":"7","author":"AV Tallet","year":"2012","unstructured":"Tallet AV, Azria D, Barlesi F et al (2012) Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol 7:77","journal-title":"Radiat Oncol"},{"key":"5362_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4161\/auto.8.2.18554","volume":"8","author":"P Maycotte","year":"2012","unstructured":"Maycotte P, Aryal S, Cummings CT et al (2012) Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy 8:200\u2013212","journal-title":"Autophagy"},{"key":"5362_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejphar.2015.12.017","volume":"771","author":"S Pascolo","year":"2016","unstructured":"Pascolo S (2016) Time to use a dose of chloroquine as an adjuvant to anti-cancer chemotherapies. Eur J Pharmacol 771:139\u2013144","journal-title":"Eur J Pharmacol"},{"key":"5362_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12883-016-0700-6","volume":"16","author":"H Ye","year":"2016","unstructured":"Ye H, Chen M, Cao F et al (2016) Chloroquine, an autophagy inhibitor, potentiates the radiosensitivity of glioma initiating cells by inhibiting autophagy and activating apoptosis. BMC Neurol 16:178","journal-title":"BMC Neurol"},{"key":"5362_CR12","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1470-2045(06)70875-0","volume":"7","author":"A Savarino","year":"2006","unstructured":"Savarino A, Lucia MB, Giordano F, Cauda R (2006) Risks and benefits of chloroquine use in anticancer strategies. Lancet Oncol 7:792\u2013793","journal-title":"Lancet Oncol"},{"key":"5362_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.canlet.2016.04.002","volume":"376","author":"DH Liang","year":"2016","unstructured":"Liang DH, Choi DS, Ensor JE et al (2016) The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair. Cancer Lett 376:249\u2013258","journal-title":"Cancer Lett"},{"key":"5362_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/0008-5472.CAN-12-2464","volume":"73","author":"T Kimura","year":"2013","unstructured":"Kimura T, Takabatake Y, Takahashi A, Isaka Y (2013) Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res 73:3\u20137","journal-title":"Cancer Res"},{"key":"5362_CR15","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","volume":"14","author":"M Mauthe","year":"2018","unstructured":"Mauthe M, Orhon I, Rocchi C et al (2018) Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy 14:1435\u20131455","journal-title":"Autophagy"},{"key":"5362_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.7326\/0003-4819-144-5-200603070-00008","volume":"144","author":"J Sotelo","year":"2006","unstructured":"Sotelo J, Brice\u00f1o E, L\u00f3pez-Gonz\u00e1lez MA (2006) Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144:337\u2013343","journal-title":"Ann Intern Med"},{"key":"5362_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-717X-8-209","volume":"8","author":"LL Rojas-Puentes","year":"2013","unstructured":"Rojas-Puentes LL, Gonzalez-Pinedo M, Crismatt A et al (2013) Phase II randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases. Radiat Oncol 8:1\u20139","journal-title":"Radiat Oncol"},{"key":"5362_CR18","doi-asserted-by":"crossref","unstructured":"Eng CH, Wang Z, Tkach D et al (2016) Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy. Proc Natl Acad Sci U S A 113:182\u2013187","DOI":"10.1073\/pnas.1515617113"},{"key":"5362_CR19","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.ijrobp.2009.02.091","volume":"76","author":"YR Lawrence","year":"2010","unstructured":"Lawrence YR, Li XA, El Naqa I et al (2010) Radiation dose\u2013volume effects in the brain. Int J Radiation Oncology* Biology* Phys 76:S20\u2013S27","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"key":"5362_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","volume":"13","author":"CM Van Leeuwen","year":"2018","unstructured":"Van Leeuwen CM, Oei AL, Crezee J et al (2018) The Alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol 13:96","journal-title":"Radiat Oncol"},{"key":"5362_CR21","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.radonc.2015.01.016","volume":"114","author":"S Scoccianti","year":"2015","unstructured":"Scoccianti S, Detti B, Gadda D et al (2015) Organs at risk in the brain and their dose-constraints in adults and in children: a radiation oncologist\u2019s guide for delineation in everyday practice. Radiother Oncol 114:230\u2013238","journal-title":"Radiother Oncol"},{"key":"5362_CR22","doi-asserted-by":"publisher","first-page":"e839","DOI":"10.1016\/j.wneu.2021.04.134","volume":"151","author":"U Beg","year":"2021","unstructured":"Beg U, Snyder BM, Madhani SI et al (2021) Current landscape and future prospects of radiation sensitizers for malignant brain tumors: a systematic review. World Neurosurg 151:e839\u2013e856","journal-title":"World Neurosurg"},{"key":"5362_CR23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3332\/ecancer.2017.781","volume":"11","author":"C Verbaanderd","year":"2017","unstructured":"Verbaanderd C, Maes H, Schaaf MB et al (2017) Repurposing Drugs in Oncology (ReDO)\u2014chloroquine and hydroxychloroquine as anti-cancer agents. Ecancermedicalscience 11:781","journal-title":"Ecancermedicalscience"},{"key":"5362_CR24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/bjc.2016.19","volume":"114","author":"MI Koukourakis","year":"2016","unstructured":"Koukourakis MI, Mitrakas AG, Giatromanolaki A (2016) Therapeutic interactions of autophagy with radiation and Temozolomide in glioblastoma: evidence and issues to resolve. Br J Cancer 114:485\u2013496","journal-title":"Br J Cancer"},{"key":"5362_CR25","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1002\/cncr.31335","volume":"124","author":"AV Onorati","year":"2018","unstructured":"Onorati AV, Dyczynski M, Ojha R, Amaravadi RK (2018) Targeting autophagy in cancer. Cancer 124:3307\u20133318","journal-title":"Cancer"},{"key":"5362_CR26","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-11-0047","volume":"10","author":"ZJ Yang","year":"2011","unstructured":"Yang ZJ, Chee CE, Huang S, Sinicrope FA (2011) The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 10:1533\u20131541","journal-title":"Mol Cancer Ther"},{"key":"5362_CR27","doi-asserted-by":"crossref","unstructured":"Annagiri S, Harary PM, Hori YS et al (2025) Radiosensitizers in cancer therapy: a global bibliometric analysis. bioRxiv 2025\u201306","DOI":"10.1101\/2025.06.26.661878"},{"key":"5362_CR28","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372","DOI":"10.1136\/bmj.n71"},{"key":"5362_CR29","doi-asserted-by":"crossref","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366","DOI":"10.1136\/bmj.l4898"},{"key":"5362_CR30","doi-asserted-by":"crossref","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355","DOI":"10.1136\/bmj.i4919"},{"key":"5362_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JP (2021) Risk-of\u2010bias visualization (robvis): an R package and Shiny web app for visualizing risk\u2010of\u2010bias assessments. Res Synthesis Methods 12:55\u201361","journal-title":"Res Synthesis Methods"},{"key":"5362_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.11124\/JBIES-22-00224","volume":"21","author":"Z Munn","year":"2023","unstructured":"Munn Z, Stone JC, Aromataris E et al (2023) Assessing the risk of bias of quantitative analytical studies: introducing the vision for critical appraisal within JBI systematic reviews. JBI Evid Synthesis 21:467\u2013471","journal-title":"JBI Evid Synthesis"},{"key":"5362_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s13566-013-0111-x","volume":"2","author":"HB Eldredge","year":"2013","unstructured":"Eldredge HB, DeNittis A, DuHadaway JB et al (2013) Concurrent whole brain radiotherapy and short-course chloroquine in patients with brain metastases: a pilot trial. J Radiation Oncol 2:315\u2013321","journal-title":"J Radiation Oncol"},{"key":"5362_CR34","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.4161\/auto.28984","volume":"10","author":"MR Rosenfeld","year":"2014","unstructured":"Rosenfeld MR, Ye X, Supko JG et al (2014) A phase I\/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10:1359\u20131368","journal-title":"Autophagy"},{"key":"5362_CR35","doi-asserted-by":"publisher","first-page":"vdaa046","DOI":"10.1093\/noajnl\/vdaa046","volume":"2","author":"L Brazil","year":"2020","unstructured":"Brazil L, Swampillai AL, Mak KM et al (2020) Hydroxychloroquine and short-course radiotherapy in elderly patients with newly diagnosed high-grade glioma: a randomized phase II trial. Neuro-Oncology Adv 2:vdaa046","journal-title":"Neuro-Oncology Adv"},{"key":"5362_CR36","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1080\/15548627.2020.1816343","volume":"17","author":"I Compter","year":"2021","unstructured":"Compter I, Eekers DB, Hoeben A et al (2021) Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. Autophagy 17:2604\u20132612","journal-title":"Autophagy"},{"key":"5362_CR37","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.surneu.2006.08.080","volume":"67","author":"E Brice\u00f1o","year":"2007","unstructured":"Brice\u00f1o E, Calderon A, Sotelo J (2007) Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol 67:388\u2013391","journal-title":"Surg Neurol"},{"key":"5362_CR38","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/cncr.31811","volume":"125","author":"S Maraka","year":"2019","unstructured":"Maraka S, Groves MD, Mammoser AG et al (2019) Phase 1 lead-in to a phase 2 factorial study of Temozolomide plus memantine, mefloquine, and Metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer 125:424\u2013433","journal-title":"Cancer"},{"key":"5362_CR39","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1080\/02688697.2021.1884648","volume":"38","author":"HM Witte","year":"2021","unstructured":"Witte HM, Riecke A, Steinestel K et al (2021) The addition of chloroquine and bevacizumab to standard radiochemotherapy for recurrent glioblastoma multiforme. Br J Neurosurg 38:404\u2013410","journal-title":"Br J Neurosurg"},{"key":"5362_CR40","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s00066-014-0693-2","volume":"190","author":"A Bilger","year":"2014","unstructured":"Bilger A, Bittner M-I, Grosu A-L et al (2014) FET-PET-based reirradiation and chloroquine in patients with recurrent glioblastoma: first tolerability and feasibility results. Strahlenther Onkol 190:957\u2013961","journal-title":"Strahlenther Onkol"},{"key":"5362_CR41","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3906\/sag-1203-100","volume":"43","author":"T Bulut","year":"2013","unstructured":"Bulut T, Ekici MA, TUCER B et al (2013) The effect of chloroquine treatment in malignant astrocytomas on prognosis. Turk J Med Sci 43:782\u2013789","journal-title":"Turk J Med Sci"},{"key":"5362_CR42","first-page":"809","volume":"20","author":"F Farhan","year":"2022","unstructured":"Farhan F, Mansouri S, Samiee F et al (2022) Concurrent administration of hydroxychloroquine and whole brain radiation therapy for patients with brain metastases. Int J Radiation Res 20:809\u2013813","journal-title":"Int J Radiation Res"},{"key":"5362_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/foc.2003.14.2.4","volume":"14","author":"E Brice\u00f1o","year":"2003","unstructured":"Brice\u00f1o E, Reyes S, Sotelo J (2003) Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. NeuroSurg Focus 14:1\u20136","journal-title":"NeuroSurg Focus"},{"key":"5362_CR44","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41418-019-0474-7","volume":"27","author":"JM Mulcahy Levy","year":"2020","unstructured":"Mulcahy Levy JM, Thorburn A (2020) Autophagy in cancer: moving from Understanding mechanism to improving therapy responses in patients. Cell Death Differ 27:843\u2013857","journal-title":"Cell Death Differ"},{"key":"5362_CR45","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1158\/1078-0432.CCR-19-4042","volume":"26","author":"HJ Zeh","year":"2020","unstructured":"Zeh HJ, Bahary N, Boone BA et al (2020) A randomized phase II preoperative study of autophagy Inhibition with high-dose hydroxychloroquine and gemcitabine\/nab-paclitaxel in pancreatic cancer patients. Clin Cancer Res 26:3126\u20133134","journal-title":"Clin Cancer Res"},{"key":"5362_CR46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41523-025-00722-1","volume":"11","author":"AS Raghavendra","year":"2025","unstructured":"Raghavendra AS, Kettner NM, Kwiatkowski D et al (2025) Phase I trial of hydroxychloroquine to enhance Palbociclib and letrozole efficacy in ER+\/HER2\u2009\u2013\u2009breast cancer. Npj Breast Cancer 11:7","journal-title":"Npj Breast Cancer"},{"key":"5362_CR47","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1093\/jnen\/60.10.937","volume":"60","author":"AU Zaidi","year":"2001","unstructured":"Zaidi AU, McDonough JS, Klocke BJ et al (2001) Chloroquine-induced neuronal cell death is p53 and Bcl-2 family-dependent but caspase-independent. J Neuropathology Experimental Neurol 60:937\u2013945","journal-title":"J Neuropathology Experimental Neurol"},{"key":"5362_CR48","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1124\/mol.105.018408","volume":"69","author":"JJ Shacka","year":"2006","unstructured":"Shacka JJ, Klocke BJ, Shibata M et al (2006) Bafilomycin A1 inhibits chloroquine-induced death of cerebellar granule neurons. Mol Pharmacol 69:1125\u20131136","journal-title":"Mol Pharmacol"},{"key":"5362_CR49","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fonc.2018.00335","volume":"8","author":"P Weyerh\u00e4user","year":"2018","unstructured":"Weyerh\u00e4user P, Kantelhardt SR, Kim EL (2018) Re-purposing chloroquine for glioblastoma: potential merits and confounding variables. Front Oncol 8:335","journal-title":"Front Oncol"},{"key":"5362_CR50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/pcmr.12547","volume":"30","author":"T Gangahdar","year":"2017","unstructured":"Gangahdar T, Schuchter L, Linette G (2017) High response rates with combined BRAF and autophagy inhibition: results of 2 phase I trials. Pigment Cell Melanoma Res 30:76\u2013156","journal-title":"Pigment Cell Melanoma Res"},{"key":"5362_CR51","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.radonc.2013.06.033","volume":"108","author":"B Jutten","year":"2013","unstructured":"Jutten B, Keulers TG, Schaaf MB et al (2013) EGFR overexpressing cells and tumors are dependent on autophagy for growth and survival. Radiother Oncol 108:479\u2013483","journal-title":"Radiother Oncol"},{"key":"5362_CR52","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/15548627.2017.1409926","volume":"14","author":"B Jutten","year":"2018","unstructured":"Jutten B, Keulers TG, Peeters HJ et al (2018) EGFRvIII expression triggers a metabolic dependency and therapeutic vulnerability sensitive to autophagy Inhibition. Autophagy 14:283\u2013295","journal-title":"Autophagy"},{"key":"5362_CR53","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1158\/2159-8290.CD-14-0049","volume":"4","author":"JMM Levy","year":"2014","unstructured":"Levy JMM, Thompson JC, Griesinger AM et al (2014) Autophagy Inhibition improves chemosensitivity in BRAFV600E brain tumors. Cancer Discov 4:773\u2013780","journal-title":"Cancer Discov"},{"key":"5362_CR54","doi-asserted-by":"publisher","first-page":"109896","DOI":"10.1016\/j.biopha.2020.109896","volume":"125","author":"Y Lei","year":"2020","unstructured":"Lei Y, Tang L, Hu J et al (2020) Inhibition of MGMT-mediated autophagy suppression decreases cisplatin chemosensitivity in gastric cancer. Biomed Pharmacother 125:109896","journal-title":"Biomed Pharmacother"},{"key":"5362_CR55","doi-asserted-by":"publisher","first-page":"21858","DOI":"10.1038\/s41598-020-77958-3","volume":"10","author":"KE Witte","year":"2020","unstructured":"Witte KE, Slotta C, L\u00fctkemeyer M et al (2020) PLEKHG5 regulates autophagy, survival and MGMT expression in U251-MG glioblastoma cells. Sci Rep 10:21858","journal-title":"Sci Rep"},{"key":"5362_CR56","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1600-065X.2008.00610.x","volume":"222","author":"JB Katz","year":"2008","unstructured":"Katz JB, Muller AJ, Prendergast GC (2008) Indoleamine 2, 3-dioxygenase in T\u2010cell tolerance and tumoral immune escape. Immunol Rev 222:206\u2013221","journal-title":"Immunol Rev"},{"key":"5362_CR57","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1172\/JCI31178","volume":"117","author":"DH Munn","year":"2007","unstructured":"Munn DH, Mellor AL (2007) Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Investig 117:1147\u20131154","journal-title":"J Clin Investig"},{"key":"5362_CR58","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-12-0014","volume":"2","author":"C Smith","year":"2012","unstructured":"Smith C, Chang MY, Parker KH et al (2012) IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2:722\u2013735","journal-title":"Cancer Discov"},{"key":"5362_CR59","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.3390\/cancers13102474","volume":"13","author":"M Khurshed","year":"2021","unstructured":"Khurshed M, Molenaar RJ, van Linde ME et al (2021) A phase Ib clinical trial of Metformin and chloroquine in patients with idh1-mutated solid tumors. Cancers 13:2474","journal-title":"Cancers"},{"key":"5362_CR60","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1021\/jm9018383","volume":"53","author":"NI Wenzel","year":"2010","unstructured":"Wenzel NI, Chavain N, Wang Y et al (2010) Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA. J Med Chem 53:3214\u20133226","journal-title":"J Med Chem"},{"key":"5362_CR61","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nature01368","volume":"421","author":"CJ Bakkenist","year":"2003","unstructured":"Bakkenist CJ, Kastan MB (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421:499\u2013506","journal-title":"Nature"},{"key":"5362_CR62","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/01.HS9.0000846668.54265.08","volume":"6","author":"TS Sl\u00f8rdahl","year":"2022","unstructured":"Sl\u00f8rdahl TS, Askeland FB, Hanssen MSS et al (2022) P950: combined proteasome and autophagy Inhibition in relapsed\/refractory multiple myeloma\u2013a phase i trial of hydroxychloroquine, Carfilzomib and dexamethasone. HemaSphere 6:840\u2013841","journal-title":"HemaSphere"},{"key":"5362_CR63","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.neo.2014.08.008","volume":"16","author":"J Biau","year":"2014","unstructured":"Biau J, Devun F, Jdey W et al (2014) A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma. Neoplasia 16:835\u2013844","journal-title":"Neoplasia"},{"key":"5362_CR64","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41420-024-02270-2","volume":"10","author":"PM Harary","year":"2024","unstructured":"Harary PM, Rajaram S, Chen MS et al (2024) Genomic predictors of radiation response: recent progress towards personalized radiotherapy for brain metastases. Cell Death Discovery 10:501","journal-title":"Cell Death Discovery"},{"key":"5362_CR65","doi-asserted-by":"publisher","first-page":"e12476","DOI":"10.15252\/emmm.202012476","volume":"12","author":"EL Nirk","year":"2020","unstructured":"Nirk EL, Reggiori F, Mauthe M (2020) Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Mol Med 12:e12476","journal-title":"EMBO Mol Med"},{"key":"5362_CR66","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.3390\/cancers14133161","volume":"14","author":"NF Brown","year":"2022","unstructured":"Brown NF, Ottaviani D, Tazare J et al (2022) Survival outcomes and prognostic factors in glioblastoma. Cancers 14:3161","journal-title":"Cancers"},{"key":"5362_CR67","first-page":"1073","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen PY, Weller M, Lee EQ et al (2020) Glioblastoma in adults: a society for Neuro-Oncology (SNO) and European society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neurooncology 22:1073\u20131113","journal-title":"Neurooncology"},{"key":"5362_CR68","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1016\/S2665-9913(20)30276-9","volume":"2","author":"JC Lane","year":"2020","unstructured":"Lane JC, Weaver J, Kostka K et al (2020) Risk of hydroxychloroquine alone and in combination with Azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol 2:e698\u2013e711","journal-title":"Lancet Rheumatol"},{"key":"5362_CR69","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s12035-020-02093-z","volume":"58","author":"W-Y Ong","year":"2021","unstructured":"Ong W-Y, Go M-L, Wang D-Y et al (2021) Effects of antimalarial drugs on neuroinflammation-potential use for treatment of COVID-19-related neurologic complications. Mol Neurobiol 58:106\u2013117","journal-title":"Mol Neurobiol"},{"key":"5362_CR70","doi-asserted-by":"crossref","unstructured":"Browning DJ (2014) Pharmacology of chloroquine and hydroxychloroquine. Hydroxychloroquine and chloroquine retinopathy. Springer, pp. 35\u201363","DOI":"10.1007\/978-1-4939-0597-3_2"},{"key":"5362_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1472-8206.1994.tb00774.x","volume":"8","author":"E Pussard","year":"1994","unstructured":"Pussard E, Verdier F (1994) Antimalarial 4-aminoquinolines: mode of action and pharmacokinetics. Fundam Clin Pharmacol 8:1\u201317","journal-title":"Fundam Clin Pharmacol"},{"key":"5362_CR72","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41419-019-1989-z","volume":"10","author":"J Gavini","year":"2019","unstructured":"Gavini J, Dommann N, Jakob MO et al (2019) Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of Sorafenib in hepatocellular carcinoma. Cell Death Dis 10:749","journal-title":"Cell Death Dis"},{"key":"5362_CR73","doi-asserted-by":"crossref","unstructured":"McAfee Q, Zhang Z, Samanta A et al (2012) Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci U S A 109:8253\u20138258","DOI":"10.1073\/pnas.1118193109"},{"key":"5362_CR74","doi-asserted-by":"publisher","first-page":"101402","DOI":"10.1016\/j.adro.2023.101402","volume":"9","author":"C Ladbury","year":"2024","unstructured":"Ladbury C, Pennock M, Yilmaz T et al (2024) Stereotactic radiosurgery in the management of brain metastases: a case-based radiosurgery society practice guideline. Adv Radiation Oncol 9:101402","journal-title":"Adv Radiation Oncol"},{"key":"5362_CR75","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ijrobp.2008.05.068","volume":"73","author":"MP Mehta","year":"2009","unstructured":"Mehta MP, Shapiro WR, Phan SC et al (2009) Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non\u2013small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 73:1069\u20131076","journal-title":"Int J Radiation Oncology* Biology* Phys"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05362-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05362-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05362-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:02:37Z","timestamp":1767704557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05362-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5362"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05362-w","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval from the Stanford University Internal Review Board was not required, as all data were obtained from the published literature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}